A drug that reduces blood sugar and promotes weight loss can cut the chances of at-risk patients developing type-2 diabetes, research shows.
An international trial found treatment with liraglutide, which interacts with brain regions that control appetite and energy intake, had a dramatic effect on diabetes risk in obese and "pre-diabetes" patients on the way to becoming chronically diabetic.
One in 10 of the UK population is thought to have pre-diabetes, a metabolic condition closely tied to obesity.
Study participants were randomly given either liraglutide or a placebo drug injected under the skin once a day for three years.
They were also placed on a reduced-kilojoule diet and advised to take more exercise.
News that makes sense
Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.
Compared with the placebo group, patients receiving the genuine treatment were 80 per cent less likely to go on to develop type-2 diabetes.
"On the basis of our findings, liraglutide ... can provide us with a new therapeutic approach for patients with obesity and pre-diabetes to substantially reduce their risk of developing type-2 diabetes and its related complications," trial leader professor John Wilding said.
Findings from the scale study, which recruited 2254 adults with pre-diabetes in 27 countries worldwide, were published in The Lancet medical journal.
